Live Earnings Conference Call: BioCardia will host a live Q1 2026 earnings call on May 15, 2026 at 4:30PM ET. Get details.

BioCardia (BCDA) Competitors

$1.09 +0.02 (+1.87%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$1.10 +0.01 (+0.92%)

As of 05/14/2026 06:45 PM Eastern

Compare

BCDA vs. ZYBT, DWTX, TLPH, MREO, and NBRV

Should you buy BioCardia stock or one of its competitors? MarketBeat compares BioCardia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioCardia include Zhengye Biotechnology (ZYBT), Dogwood Therapeutics (DWTX), Talphera (TLPH), Mereo BioPharma Group (MREO), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry.

How does BioCardia compare to Zhengye Biotechnology?

BioCardia (NASDAQ:BCDA) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, BioCardia had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for BioCardia and 2 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.44 beat BioCardia's score of 0.78 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
BioCardia	Positive
Zhengye Biotechnology	Positive

20.6% of BioCardia shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zhengye Biotechnology's return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-28,372.40%	-238.22%
Zhengye Biotechnology	N/A	N/A	N/A

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,193.58%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioCardia has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	198.74	-$8.23M	-$1.29	N/A
Zhengye Biotechnology	$16.64M	2.71	-$9.98M	N/A	N/A

BioCardia has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, suggesting that its share price is 347% less volatile than the broader market.

Summary

BioCardia beats Zhengye Biotechnology on 9 of the 13 factors compared between the two stocks.

How does BioCardia compare to Dogwood Therapeutics?

BioCardia (NASDAQ:BCDA) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

BioCardia has higher revenue and earnings than Dogwood Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	198.74	-$8.23M	-$1.29	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$18.90	N/A

Dogwood Therapeutics' return on equity of -2,027.44% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-28,372.40%	-238.22%
Dogwood Therapeutics	N/A	-2,027.44%	-31.29%

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 0.2% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BioCardia and BioCardia both had 5 articles in the media. BioCardia's average media sentiment score of 0.78 beat Dogwood Therapeutics' score of 0.22 indicating that BioCardia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCardia presently has a consensus target price of $25.00, suggesting a potential upside of 2,193.58%. Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 506.06%. Given BioCardia's higher possible upside, analysts clearly believe BioCardia is more favorable than Dogwood Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioCardia has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

Summary

BioCardia beats Dogwood Therapeutics on 7 of the 11 factors compared between the two stocks.

How does BioCardia compare to Talphera?

Talphera (NASDAQ:TLPH) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, Talphera had 5 more articles in the media than BioCardia. MarketBeat recorded 10 mentions for Talphera and 5 mentions for BioCardia. BioCardia's average media sentiment score of 0.78 beat Talphera's score of 0.65 indicating that BioCardia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

37.7% of Talphera shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 3.5% of Talphera shares are held by insiders. Comparatively, 17.4% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Talphera presently has a consensus target price of $3.00, indicating a potential upside of 234.26%. BioCardia has a consensus target price of $25.00, indicating a potential upside of 2,193.58%. Given BioCardia's higher possible upside, analysts clearly believe BioCardia is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Talphera has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

BioCardia has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,552.68	-$14.29M	-$0.37	N/A
BioCardia	$60K	198.74	-$8.23M	-$1.29	N/A

Talphera's return on equity of -99.81% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-99.81%	-55.55%
BioCardia	N/A	-28,372.40%	-238.22%

Summary

Talphera beats BioCardia on 7 of the 13 factors compared between the two stocks.

How does BioCardia compare to Mereo BioPharma Group?

BioCardia (NASDAQ:BCDA) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Mereo BioPharma Group had 3 more articles in the media than BioCardia. MarketBeat recorded 8 mentions for Mereo BioPharma Group and 5 mentions for BioCardia. BioCardia's average media sentiment score of 0.78 beat Mereo BioPharma Group's score of -0.23 indicating that BioCardia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mereo BioPharma Group	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCardia has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Mereo BioPharma Group's return on equity of -81.28% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-28,372.40%	-238.22%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

BioCardia currently has a consensus target price of $25.00, indicating a potential upside of 2,193.58%. Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 1,221.14%. Given BioCardia's higher probable upside, equities research analysts plainly believe BioCardia is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

BioCardia has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	198.74	-$8.23M	-$1.29	N/A
Mereo BioPharma Group	$500K	78.53	-$41.88M	-$0.05	N/A

Summary

Mereo BioPharma Group beats BioCardia on 8 of the 15 factors compared between the two stocks.

How does BioCardia compare to Nabriva Therapeutics?

Nabriva Therapeutics (NASDAQ:NBRV) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

BioCardia has a consensus price target of $25.00, suggesting a potential upside of 2,193.58%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, BioCardia had 5 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 5 mentions for BioCardia and 0 mentions for Nabriva Therapeutics. BioCardia's average media sentiment score of 0.78 beat Nabriva Therapeutics' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.

Company	Overall Sentiment
Nabriva Therapeutics	Neutral
BioCardia	Positive

BioCardia has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Nabriva Therapeutics' return on equity of -365.53% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
BioCardia	N/A	-28,372.40%	-238.22%

BioCardia has lower revenue, but higher earnings than Nabriva Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A
BioCardia	$60K	198.74	-$8.23M	-$1.29	N/A

Nabriva Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, BioCardia has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Comparatively, 17.4% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

BioCardia beats Nabriva Therapeutics on 10 of the 15 factors compared between the two stocks.

Get BioCardia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCDA vs. The Competition

Export

Metric	BioCardia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.71M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.84	18.47	20.66	25.63
Price / Sales	198.74	294.84	549.87	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	13.63	6.93	9.93	6.97
Net Income	-$8.23M	$24.11M	$3.55B	$333.62M
7 Day Performance	-1.80%	5.89%	1.71%	1.09%
1 Month Performance	-8.40%	-0.91%	0.49%	3.08%
1 Year Performance	-53.02%	74.58%	39.41%	35.68%

BioCardia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCDA BioCardia	4.1483 of 5 stars	$1.09 +1.9%	$25.00 +2,193.6%	-60.6%	$11.71M	$60K	N/A	40
ZYBT Zhengye Biotechnology	1.0919 of 5 stars	$0.95 -5.0%	N/A	-88.7%	$47.15M	$16.64M	N/A	278	Positive News Short Interest Decrease
DWTX Dogwood Therapeutics	2.3142 of 5 stars	$1.44 +2.1%	$12.00 +733.3%	-59.2%	$47.10M	N/A	N/A	5	Earnings Report Short Interest Increase Gap Down
TLPH Talphera	3.3092 of 5 stars	$0.90 +1.4%	$3.00 +232.3%	+76.0%	$46.22M	$30K	N/A	19	News Coverage Earnings Report
MREO Mereo BioPharma Group	3.2056 of 5 stars	$0.28 -2.9%	$3.25 +1,066.1%	-89.4%	$45.83M	$500K	N/A	40	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCDA) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCardia (BCDA) Competitors

BCDA vs. ZYBT, DWTX, TLPH, MREO, and NBRV

How does BioCardia compare to Zhengye Biotechnology?

Summary

How does BioCardia compare to Dogwood Therapeutics?

Summary

How does BioCardia compare to Talphera?

Summary

How does BioCardia compare to Mereo BioPharma Group?

Summary

How does BioCardia compare to Nabriva Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCardia (BCDA) Competitors

BCDA vs. ZYBT, DWTX, TLPH, MREO, and NBRV

How does BioCardia compare to Zhengye Biotechnology?

Does the media refer more to BCDA or ZYBT?

Do institutionals & insiders have more ownership in BCDA or ZYBT?

Is BCDA or ZYBT more profitable?

Do analysts rate BCDA or ZYBT?

Which has better earnings & valuation, BCDA or ZYBT?

Which has more risk and volatility, BCDA or ZYBT?

Summary

How does BioCardia compare to Dogwood Therapeutics?

Which has higher valuation and earnings, BCDA or DWTX?

Is BCDA or DWTX more profitable?

Do institutionals and insiders hold more shares of BCDA or DWTX?

Does the media prefer BCDA or DWTX?

Do analysts prefer BCDA or DWTX?

Which has more volatility & risk, BCDA or DWTX?

Summary

How does BioCardia compare to Talphera?

Does the media favor TLPH or BCDA?

Do institutionals & insiders believe in TLPH or BCDA?

Do analysts recommend TLPH or BCDA?

Which has more risk and volatility, TLPH or BCDA?

Which has better valuation & earnings, TLPH or BCDA?

Is TLPH or BCDA more profitable?

Summary

How does BioCardia compare to Mereo BioPharma Group?

Do insiders and institutionals have more ownership in BCDA or MREO?

Does the media prefer BCDA or MREO?

Which has more risk and volatility, BCDA or MREO?

Is BCDA or MREO more profitable?

Do analysts rate BCDA or MREO?

Which has stronger earnings and valuation, BCDA or MREO?

Summary

How does BioCardia compare to Nabriva Therapeutics?

Do analysts rate NBRV or BCDA?

Does the media refer more to NBRV or BCDA?

Is NBRV or BCDA more profitable?

Which has stronger valuation and earnings, NBRV or BCDA?

Which has more risk & volatility, NBRV or BCDA?

Do institutionals & insiders have more ownership in NBRV or BCDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools